Meanwhile, Satonaka et al. (2017) confirmed EGCG reversed the above doxorubicin resistance in hepatoma cells by synergistically inhibiting MAPK/ERK and PI3K/Akt signaling pathways. The gene discussed is AKT1; the disease is hepatocellular carcinoma.